JETCRAFT
17.11.2020 13:02:14 CET | Business Wire | Press release
Jetcraft , the world leader in business jet sales and acquisitions, is releasing a 5-Year Pre-Owned Business Aviation Market Forecast – including, for the first time, trends from the company’s own past transactional data and customer insights.
The latest forecast predicts pre-owned transaction volume and value will recover to steady growth during the five-year period, in spite of the challenges this year, reaching 2,271 transactions worth $11.1B annually by 2024.
Jahid Fazal-Karim, Owner and Chairman of the Board at Jetcraft, says: “Covid-19 has affected many industries, including our own. However, business aviation has started to recover and the reduction in commercial flight activity provides a real opportunity for the sector to further expand its customer base and secure long-term prosperity.
“For this year’s forecast we’ve decided to focus our predictions solely on the pre-owned market, a particular area of strength for Jetcraft and one that isn’t often included in other industry reports. Our forecast shows business aviation has begun to stabilize from the effect of the pandemic, and we expect to see 10,183 pre-owned transactions worth $48.8B in value over the next five years.”
Jetcraft’s forecast highlights trends in international trade activity that bode well for industry growth. Despite temporarily reduced activity in 2020, the World Trade Organization projects trade volume will rebound in 2021. Another key driver in business aviation transactions is the increase in the number of ultra-high net worth individuals (UHNWIs), which is set to grow by 5% per annum until 2024.
Fazal-Karim continues: “Our previous forecasts predicted a downturn. Although it has taken place sooner than we thought, we were prepared and, as a result, are in a stronger position than in 2008. We have seen our industry quickly regain momentum and I’m confident in its recovery, particularly with more first-time buyers realizing the value of business aviation, and the addition of new platforms which continue to improve accessibility.”
Drawing upon nearly 60 years of industry knowledge, this is the first year that Jetcraft’s Market Forecast is incorporating past transactional data and customer insights, delivering a unique look at buyer behavior.
Fazal-Karim concludes: “We are forecasting a continued increase in Large Jet transactions, albeit at a slower pace than in previous years. Our Jetcraft transactional data shows Large Jets representing a strong share of purchases by younger buyers, and that High Net Worth buyer types, as compared to Corporate or Government buyer types, are more likely to invest in this aircraft segment. These trends truly demonstrate the potential of the Large Jet category, which remains poised for long-term growth.
“Predicting the future is certainly more challenging against the backdrop of the current climate, and I’m especially proud to be sharing our anticipated annual industry outlook again this year.”
Jetcraft’s complete 2020 5-year Pre-Owned Business Aviation Market Forecast is available to download at https://www.jetcraft.com/knowledge/market-forecast/ .
ENDS
Report graphs, high-resolution images and interviews are available on request.
About Jetcraft
Jetcraft is the leader in international aircraft sales, marketing and ownership strategies, managing and maintaining over 20 regional offices globally. The company’s unparalleled success over more than 55 years in business aviation has earned it a world-class reputation, along with an exceptional customer base, a wide network of connections and one of the largest inventories within the industry.
For more information, please visit www.jetcraft.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005566/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom